Investigational immunotherapeutic increased bladder cancer survival

Among patients with metastatic bladder cancer that had progressed after platinum-based chemotherapy, those who received an investigational, personalized peptide cancer vaccine and best-supportive care had extended overall survival compared with those who received best-supportive care alone, according to results from a randomized, phase II clinical.

from Today's Healthcare News -- ScienceDaily http://ift.tt/1SDZrFy